Fiche publication
Date publication
novembre 2024
Journal
Alimentary pharmacology & therapeutics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Swaminathan A, Day AS, Sparrow MP, Peyrin-Biroulet L, Siegel CA, Gearry RB
Lien Pubmed
Résumé
Inflammatory bowel disease (IBD) follows a heterogenous disease course and predicting a patient's prognosis is challenging. There is a wide burden of illness in IBD and existing tools measure disease activity at a snapshot in time. Comprehensive assessment of IBD severity should incorporate disease activity, prognosis, and the impacts of disease on a patient. This review investigates the concept of disease severity in adults with IBD to highlight key components contributing to this.
Mots clés
Humans, Severity of Illness Index, Quality of Life, Inflammatory Bowel Diseases, therapy, Prognosis, Colitis, Ulcerative, diagnosis, Cost of Illness, Crohn Disease, therapy
Référence
Aliment Pharmacol Ther. 2024 11;60(9):1176-1199
